Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.

Annino L, Chierichini A, Anaclerico B, Finolezzi E, Norata M, Cortese S, Cassetta MI, Fallani S, Novelli A, Girmenia C.

Antimicrob Agents Chemother. 2013 Jun;57(6):2596-602. doi: 10.1128/AAC.00155-13.

2.
3.

Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.

Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E.

Cancer. 2004 Feb 1;100(3):581-9.

4.

Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.

Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, Monchecourt F, Mahi L, Ribaud P.

Int J Antimicrob Agents. 2008 Feb;31(2):135-41.

PMID:
18162375
5.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
6.

Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients.

Karthaus M, Doellmann T, Klimasch T, Elser C, Rosenthal C, Ganser A, Heil G.

Chemotherapy. 2000 Jul-Aug;46(4):293-302.

PMID:
10859435
7.

Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.

Mandhaniya S, Swaroop C, Thulkar S, Vishnubhatla S, Kabra SK, Xess I, Bakhshi S.

J Pediatr Hematol Oncol. 2011 Dec;33(8):e333-41. doi: 10.1097/MPH.0b013e3182331bc7.

PMID:
22042283
9.

High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial.

Giannella M, Ercolani G, Cristini F, Morelli M, Bartoletti M, Bertuzzo V, Tedeschi S, Faenza S, Puggioli C, Lewis RE, Pinna AD, Viale P.

Transplantation. 2015 Apr;99(4):848-54. doi: 10.1097/TP.0000000000000393.

PMID:
25531982
10.

Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.

Arrieta AC, Shea K, Dhar V, Cleary JP, Kukreja S, Morris M, Vargas-Shiraishi OM, Ashouri N, Singh J.

Clin Ther. 2010 Feb;32(2):265-71. doi: 10.1016/j.clinthera.2010.02.016.

PMID:
20206784
11.

Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.

Chong GL, Broekman F, Polinder S, Doorduijn JK, Lugtenburg PJ, Verbon A, Cornelissen JJ, Rijnders BJ.

Int J Antimicrob Agents. 2015 Jul;46(1):82-7. doi: 10.1016/j.ijantimicag.2015.02.023.

PMID:
25956843
12.

Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.

Sunakawa K, Tsukimoto I, Tsunematsu Y, Honda M, Iwai N, Maniwa T, Haigo H, Suzuki K, Mori T.

J Infect Chemother. 2012 Aug;18(4):456-65.

PMID:
22286407
13.

A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever.

Ellis M, Bernsen R, Ali-Zadeh H, Kristensen J, Hedström U, Poughias L, Bresnik M, Al-Essa A, Stevens DA.

J Med Microbiol. 2009 Nov;58(Pt 11):1474-85. doi: 10.1099/jmm.0.012401-0.

PMID:
19589901
14.

Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

Tiphine M, Letscher-Bru V, Herbrecht R.

Transpl Infect Dis. 1999 Dec;1(4):273-83. Review.

PMID:
11428998
15.
16.

Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.

Morello E, Pagani L, Coser P, Cavattoni I, Cortelazzo S, Casini M, Billio A, Rossi G.

Bone Marrow Transplant. 2011 Jan;46(1):132-6. doi: 10.1038/bmt.2010.76.

PMID:
20383205
17.

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.

Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE.

Br J Haematol. 1997 Sep;98(3):711-8.

PMID:
9332329
18.
19.

Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia.

Noguchi S, Takahashi N, Ito M, Teshima K, Yamashita T, Michishita Y, Ohyagi H, Shida S, Nagao T, Fujishima M, Ikeda S, Ito I, Fujishima N, Kameoka Y, Saitoh H, Tagawa H, Hirokawa M, Sawada K.

Int J Clin Oncol. 2013 Dec;18(6):983-7. doi: 10.1007/s10147-012-0485-6.

PMID:
23076821
20.

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg RN, Dummer S, Schuster M, Holcenberg JS.

N Engl J Med. 1999 Mar 11;340(10):764-71.

Items per page

Supplemental Content

Support Center